Loss ofCDKN2Aexpression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines

Differential mechanisms ofCDKN2A(p16) alteration in oral tongue squamous cell carcinomas and correlation with patient outcome

(2014) Annette M. Lim et al.   INTERNATIONAL JOURNAL OF CANCER

The Cell-Cycle Regulator CDK4: An Emerging Therapeutic Target in Melanoma

(2013) K. E. Sheppard et al.   CLINICAL CANCER RESEARCH

Targeting cell cycle and hormone receptor pathways in cancer

(2013) C E S Comstock et al.   ONCOGENE

Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma

(2012) J. P. Leonard et al.   BLOOD

Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors

(2012) Jeffry L. Dean et al.   CELL CYCLE

A High-Throughput Panel for Identifying Clinically Relevant Mutation Profiles in Melanoma

(2012) K. Dutton-Regester et al.   MOLECULAR CANCER THERAPEUTICS

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

(2012) Jordi Barretina et al.   NATURE

Expression of p16 and Retinoblastoma Determines Response to CDK4/6 Inhibition in Ovarian Cancer

(2011) Gottfried E. Konecny et al.   CLINICAL CANCER RESEARCH

Prognostic and Clinicopathologic Associations of OncogenicBRAFin Metastatic Melanoma

(2011) Georgina V. Long et al.   JOURNAL OF CLINICAL ONCOLOGY

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma

(2011) Bianca Devitt et al.   Pigment Cell & Melanoma Research

Pharmacologic Inhibition of Cyclin-Dependent Kinases 4 and 6 Arrests the Growth of Glioblastoma Multiforme Intracranial Xenografts

(2010) K. Michaud et al.   CANCER RESEARCH

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

(2010) Jacques Ferlay et al.   INTERNATIONAL JOURNAL OF CANCER

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

(2010) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer

(2010) S. A. Forbes et al.   NUCLEIC ACIDS RESEARCH

Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure

(2010) Despina Handolias et al.   Pigment Cell & Melanoma Research

The Association between MC1R Genotype and BRAF Mutation Status in Cutaneous Melanoma: Findings from an Australian Population

(2009) Elke Hacker et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY